Moderna (MRNA) PT Raised to $137 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $258.38 +13.11%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter raised the price target on Moderna (NASDAQ: MRNA) to $137.00 (from $120.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Moderna (MRNA) call put ratio 1.1 calls to 1 put into quarter results
- Moderna's Bundibugyo ebolavirus vaccine moves to Phase 2/3 trial
- Pfizer (PFE) PT Raised to $40 at Argus
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
